ICR, a leading strategic communications and advisory firm, today announced that it will host the virtual “ICR Healthcare Symposium: Biotech Investment Landscape – Sell Side Perspective” on Thursday, October 13, 2022 at 12 p.m. ET.
The event will focus on the latest biotech investment trends and sector outlook in the current challenging environment from the perspective of sell side analyst guest speakers, Josh Schimmer, Evercore ISI, and Andrew Tsai, Jefferies. They will offer invaluable insight and predictions about what to expect in 2023.
The speakers will explore topics around company positioning, public or private, for a favorable investment profile including:
- Stage of pipeline development
- Timing for the next expected data readouts
- Positioning in the most exciting MOAs
- Exposure to appealing disease targets
- Access to capital
- Quality of existing investors
- Depth of management experience
If you would like additional information, please contact ICREvents@icrinc.com.
About ICR
Established in 1998, ICR partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. The firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to approximately 1,000 clients across more than 20 industry groups. ICR’s healthcare practice operates under the Westwicke brand (www.westwicke.com). Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America, maintaining offices in New York, Norwalk, Boston, Baltimore and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005309/en/
